Altimmune (NASDAQ:ALT) Rating Reiterated by B. Riley

Altimmune (NASDAQ:ALT)‘s stock had its “buy” rating reaffirmed by stock analysts at B. Riley in a report issued on Tuesday, Benzinga reports. They presently have a $20.00 price objective on the stock. B. Riley’s price target indicates a potential upside of 219.74% from the stock’s previous close.

ALT has been the topic of a number of other reports. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Altimmune in a research report on Tuesday, May 14th. JMP Securities dropped their price objective on shares of Altimmune from $25.00 to $24.00 and set a “market outperform” rating on the stock in a report on Friday, May 10th. Piper Sandler reissued an “overweight” rating and set a $25.00 price objective on shares of Altimmune in a report on Friday, June 21st. Finally, Guggenheim lowered shares of Altimmune from a “buy” rating to a “neutral” rating in a report on Monday, April 29th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $18.80.

Altimmune Trading Down 15.6 %

Shares of ALT stock opened at $6.26 on Tuesday. The business’s fifty day simple moving average is $7.09 and its 200-day simple moving average is $8.78. The company has a market cap of $443.48 million, a PE ratio of -3.93 and a beta of 0.11. Altimmune has a 12-month low of $2.09 and a 12-month high of $14.84.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.02. The business had revenue of $0.01 million for the quarter. Altimmune had a negative return on equity of 46.96% and a negative net margin of 22,645.37%. During the same period in the previous year, the company posted ($0.40) earnings per share. On average, equities analysts forecast that Altimmune will post -1.34 earnings per share for the current year.

Institutional Investors Weigh In On Altimmune

A number of large investors have recently made changes to their positions in the stock. WealthPlan Investment Management LLC purchased a new stake in Altimmune in the third quarter valued at $31,000. North Star Investment Management Corp. purchased a new stake in Altimmune in the first quarter valued at $31,000. FNY Investment Advisers LLC purchased a new stake in Altimmune in the fourth quarter valued at $35,000. CANADA LIFE ASSURANCE Co purchased a new stake in Altimmune in the first quarter valued at $44,000. Finally, Russell Investments Group Ltd. boosted its stake in shares of Altimmune by 1,150.9% during the 4th quarter. Russell Investments Group Ltd. now owns 4,303 shares of the company’s stock worth $48,000 after acquiring an additional 3,959 shares in the last quarter. 78.05% of the stock is owned by hedge funds and other institutional investors.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.